Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Lynn Henry

Showing results (121-130 of 195) with videos related to

Pageof 20
Sort By:
Breast Cancer Research and Treatment|June 24, 2017
Variable aromatase inhibitor plasma concentrations do not correlate with circulating estrogen concentrations in post-menopausal breast cancer patientsDaniel L Hertz, Kelly A Speth, Kelley M Kidwell, et al.
Cell Reports. Medicine|March 8, 2025
A circadian and app-based personalized lighting intervention for the reduction of cancer-related fatigueCaleb Mayer, Olivia Walch, Walter Dempsey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 4, 2022
Sex Differences in Risk of Severe Adverse Events in Patients Receiving Immunotherapy, Targeted Therapy, or Chemotherapy in Cancer Clinical TrialsJoseph M Unger, Riha Vaidya, Kathy S Albain, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2012
Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancerN Lynn Henry, Faouzi Azzouz, Zereunesay Desta, et al.
Pharmacogenetics and Genomics|June 7, 2021
Genome-wide association study of letrozole plasma concentrations identifies non-exonic variants that may affect CYP2A6 metabolic activityDaniel L Hertz, Julie A Douglas, Kelley M Kidwell, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|July 18, 2023
Adverse Health Outcomes among Rural and Urban Breast Cancer Survivors: A Population-Based Cohort StudyAlzina Koric, Bayarmaa Mark, Chun-Pin Chang, et al.
Cancer|October 22, 2025
Analyses of adverse events and patient-reported outcomes with the toxicity index in cancer clinical trialsGillian Gresham, N Lynn Henry, Hanna Bandos, et al.
Journal of Cancer Survivorship : Research and Practice|March 23, 2024
Barriers to endocrine therapy adherence: perspectives of Black breast cancer survivors and their providersKimberley T Lee, Brian D Gonzalez, Carley Geiss, et al.
Clinical Pharmacology and Therapeutics|May 10, 2023
Confirmatory DPYD Testing in Patients Receiving Fluoropyrimidines Who are Suspected DPYD Variant Carriers Based on a Genetic Data RepositoryAmy L Pasternak, Robinson Seda, Joseph Lipa, et al.
Breast Cancer Research and Treatment|March 14, 2020
Vitamin D deficiency increases severity of paclitaxel-induced peripheral neuropathyTheodore S Jennaro, Fang Fang, Kelley M Kidwell, et al.
Pageof 20

Showing results (121-130 of 195) with videos related to

Sort By:
Pageof 20
Breast Cancer Research and Treatment|June 24, 2017
Variable aromatase inhibitor plasma concentrations do not correlate with circulating estrogen concentrations in post-menopausal breast cancer patientsDaniel L Hertz, Kelly A Speth, Kelley M Kidwell, et al.
Cell Reports. Medicine|March 8, 2025
A circadian and app-based personalized lighting intervention for the reduction of cancer-related fatigueCaleb Mayer, Olivia Walch, Walter Dempsey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 4, 2022
Sex Differences in Risk of Severe Adverse Events in Patients Receiving Immunotherapy, Targeted Therapy, or Chemotherapy in Cancer Clinical TrialsJoseph M Unger, Riha Vaidya, Kathy S Albain, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2012
Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancerN Lynn Henry, Faouzi Azzouz, Zereunesay Desta, et al.
Pharmacogenetics and Genomics|June 7, 2021
Genome-wide association study of letrozole plasma concentrations identifies non-exonic variants that may affect CYP2A6 metabolic activityDaniel L Hertz, Julie A Douglas, Kelley M Kidwell, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|July 18, 2023
Adverse Health Outcomes among Rural and Urban Breast Cancer Survivors: A Population-Based Cohort StudyAlzina Koric, Bayarmaa Mark, Chun-Pin Chang, et al.
Cancer|October 22, 2025
Analyses of adverse events and patient-reported outcomes with the toxicity index in cancer clinical trialsGillian Gresham, N Lynn Henry, Hanna Bandos, et al.
Journal of Cancer Survivorship : Research and Practice|March 23, 2024
Barriers to endocrine therapy adherence: perspectives of Black breast cancer survivors and their providersKimberley T Lee, Brian D Gonzalez, Carley Geiss, et al.
Clinical Pharmacology and Therapeutics|May 10, 2023
Confirmatory DPYD Testing in Patients Receiving Fluoropyrimidines Who are Suspected DPYD Variant Carriers Based on a Genetic Data RepositoryAmy L Pasternak, Robinson Seda, Joseph Lipa, et al.
Breast Cancer Research and Treatment|March 14, 2020
Vitamin D deficiency increases severity of paclitaxel-induced peripheral neuropathyTheodore S Jennaro, Fang Fang, Kelley M Kidwell, et al.
Pageof 20